AMENDMENTS

1. (Currently amended) A composition ~~for inhibition of inducible COX-2 activity and having minimal effect on COX-1 activity, said composition~~ comprising, as a first component an effective amount of a sesquiterpene lactone species and an effective amount of a second component selected from the group consisting of a diterpene lactone species and a triterpene species or derivatives thereof, wherein said composition inhibits inducible COX-2 activity and has minimal effect on COX-1 activity.

2. (Previously presented) The composition of claim 1 wherein said first and second components are derived from plants or plant extracts.

3. (Original) The composition of claim 1 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

4. (Original) The composition of claim 1, formulated in a pharmaceutically acceptable carrier.

5. (Previously presented) The composition of claim 1, additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

6. (Previously presented) A composition of Claim 1, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, aneoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

7. (Original) The composition of claim 6 wherein first and second components are derived from plants or plant extracts.

8. (Original) The composition of claim 6 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

9. (Original) The composition of claim 6, formulated in a pharmaceutically acceptable carrier.

10. (Previously presented) The composition of claim 6, additionally containing one or members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

11. (Previously presented) A composition of Claim 1, wherein, the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

12. (Original) The composition of claim 11 wherein first and second components are derived from plants or plant extracts.

13. (Original) The composition of claim 11 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

14. (Original) The composition of claim 11, formulated in a pharmaceutically acceptable carrier.

15. (Previously presented) The composition of claim 11, additionally containing one or members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

16. (Currently amended) A composition ~~of Claim 1, wherein, the~~ comprising a first component ~~comprises~~ comprising parthenolide and ~~[[the]]~~ a second component ~~[[is]]~~ selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

17. (Original) The composition of claim 16 wherein first and second components are derived from plants or plant extracts.

18. (Original) The composition of claim 16 wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

19. (Original) The composition of claim 16, formulated in a pharmaceutically acceptable carrier.

20. (Previously presented) The composition of claim 16, additionally containing one or members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

21. (Withdrawn) A method of dietary supplementation in animals comprising administering to an animal suffering symptoms of inflammation a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

22. (Withdrawn) The method of claim 21 wherein the composition is formulated in a dosage form such that said administration provides from 0.05 to 5.0 mg body weight per day of each sesquiterpene lactone species, and from 0.5 to 20.0 mg/kg bodyweight per day of each diterpene lactone species or triterpene species.

23. (Withdrawn) The method of claim 21, wherein the composition is administered in an amount sufficient to maintain a serum concentration of 0.001 to 10 μM of each sesquiterpene lactone species and from 0.001 to 10 μM of each diterpene lactone or triterpene species.

24. (Withdrawn) The method of claim 21 wherein said animal is selected from the group consisting of humans, non-human primates, dogs, cats, birds, horses and ruminants.

25. (Withdrawn) The method of claim 21 wherein administration is by a means selected from the group consisting of oral, parenteral, topical, transdermal and transmucosal delivery.

26. (Withdrawn) The method of Claim 21, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, aneoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

27. (Withdrawn) The method of claim 26 wherein the composition is formulated in a dosage form such that said administration provides from 0.05 to 5.0 mg body weight per day of each sesquiterpene lactone species, and from 0.5 to 20.0 mg/kg bodyweight per day of each diterpene lactone species or triterpene species.

28. (Withdrawn) The method of claim 26, wherein the composition is administered in an amount sufficient to maintain a serum concentration of 0.001 to 10 μM of each sesquiterpene lactone species and from 0.001 to 10 μM of each diterpene lactone or triterpene species.

29. (Withdrawn) The method of Claim 21, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

30. (Withdrawn) The method of Claim 21, wherein the first component comprises parthenolide and; the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

31. (Withdrawn) The method of therapeutic treatment in animals comprising administering to an animal suffering symptoms of arthritis a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

32. (Withdrawn) The method of Claim 31, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

33. (Withdrawn) The method of Claim 31, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

34. (Withdrawn) The method of Claim 31, wherein the first component comprises parthenolide and the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

35. (Withdrawn) A method of therapeutic treatment comprising applying to the skin of a human suffering symptoms of acne rosacea a lotion comprising a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

36. (Withdrawn) The method of Claim 35, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin,

melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

37. (Withdrawn) The method of Claim 35, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

38. (Withdrawn) The method of Claim 35, wherein the first component comprises parthenolide and the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

39. (Withdrawn) A method of therapeutic treatment comprising applying to the skin of a human suffering symptoms of psoriasis a lotion comprising a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

40. (Withdrawn) The method of Claim 39, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

41. (Withdrawn) The method of Claim 39, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of

andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

42. (Withdrawn) The method of Claim 39, wherein the first component comprises parthenolide and the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

43. (Previously presented) A composition comprising, as a first component, an effective amount of a pharmaceutical grade sesquiterpene lactone species and an effective amount of a second component selected from the group consisting of a pharmaceutical grade diterpene lactone species and a triterpene species or derivatives thereof.

44. (Previously presented) The composition of claim 43, wherein the first and second components are derived from plants or plant extracts.

45. (Previously presented) The composition of claim 43, wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

46. (Previously presented) The composition of claim 43, formulated in a pharmaceutically acceptable carrier.

47. (Previously presented) The composition of claim 43, additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

48. (Previously presented) The composition of claim 43, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapomdin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol and helenalin; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, aneoandrographolide,

ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

49. (Previously presented) The composition of claim 48, wherein the first and second components are derived from plants or plant extracts.

50. (Previously presented) The composition of claim 48, wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

51. (Previously presented) The composition of claim 48, formulated in a pharmaceutically acceptable carrier.

52. (Previously presented) The composition of claim 48, additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

53. (Previously presented) A composition of claim 43, wherein, the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapomdin A; and the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

54. (Previously presented) The composition of claim 53, wherein the first and second components are derived from plants or plant extracts.

55. (Previously presented) The composition of claim 53, wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

56. (Previously presented) The composition of claim 53, formulated in a pharmaceutically acceptable carrier.

57. (Previously presented) The composition of claim 53, additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

58. (Currently amended) A composition ~~of claim 43, wherein, the~~ comprising as a first component ~~comprises~~ an effective amount of pharmaceutical grade parthenolide and an effective amount of a pharmaceutical grade ~~[[the]]~~ second component ~~[[is]]~~ selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

59. (Previously presented) The composition of claim 58, wherein the first and second components are derived from plants or plant extracts.

60. (Previously presented) The composition of claim 58, wherein at least one of said first or second component is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.

61. (Previously presented) The composition of claim 58, formulated in a pharmaceutically acceptable carrier.

62. (Previously presented) The composition of claim 58, additionally containing one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and aminosugars.

Please add the following new claims.

63. (New) The composition of claim 1, wherein the first component comprises costunolide.

64. (New) The composition of claim 1, wherein the second component comprises glycyrrhizic acid.